Lantern Pharma is trading at $1.62, down 7.95%, while the immediate catalyst remains unclear.
- No clear company-specific announcement was identified for September 11, 2026; available coverage primarily references earlier second-quarter results and clinical updates.
- The decline comes despite provided pre-market gains in major U.S. indices, so broader market sentiment does not clearly explain the move.
- Weakness has continued across several sessions; further monitoring is warranted for delayed company news or filings.